Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.
Donal T SkellyAdam C HardingJavier Gilbert JaramilloMichael L KnightStéphanie LongetAnthony BrownSandra AdeleEmily AdlandHelen Brownnull nullT R W TiptonLizzie StaffordAlexander J MentzerSíle A JohnsonAli Amininull nullTiong Kit TanLisa SchimanskiKuan-Ying A HuangPramila Rijalnull nullnull nullJohn FraterPhilip GoulderChristopher P ConlonKatie JefferyChristina DoldAndrew J PollardAlex SigalTulio de OliveiraAlain R TownsendPaul KlenermanSusanna J DunachieEleanor BarnesMiles W CarrollWilliam S JamesPublished in: Nature communications (2021)
The extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is of increasing importance. Accordingly, here we analyse antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020. We show that neutralization of the VOC compared to a reference isolate of the original circulating lineage, B, is reduced: more profoundly against B.1.351 than for B.1.1.7, and in responses to infection or a single dose of vaccine than to a second dose of vaccine. Importantly, high magnitude T cell responses are generated after two vaccine doses, with the majority of the T cell response directed against epitopes that are conserved between the prototype isolate B and the VOC. Vaccination is required to generate high potency immune responses to protect against these and other emergent variants.